PROM1 and glioblastoma: Recently, in glioblastoma, Ricci-Vitiani et al(32) and Wang et al(33) found that CD133+ glioblastoma stem-like cells are pluripotent and capable of differentiation along tumor and endothelial lineages (33,66), as well as mixed endothelial cell lineages, with co-expression of the tumor phenotype (32).